Background Tumor necrosis factor inhibitors decrease the risk of cardiovascular events in
Introduction
Psoriasis is a common and chronic inflammatory skin disease which is pathologically characterized by an aberrant crosstalk between keratinocytes and immune cells. Clinical studies and basic researches in the recent decade have demonstrated the close association of psoriasis with comorbid diseases, such as obesity, hypertension, diabetes, dyslipidemia, metabolic syndrome, cardiovascular disorders, inflammatory bowel disease, hepatic disease, chronic kidney disease, malignancy, infection, mood disorders, and psoriatic arthritis. 1 Among various molecules associated with disease development and progression, tumor necrosis factor (TNF)-a has attracted much attention as a key cytokine which potentially explains the relation of psoriasis with its systemic comorbidities, particularly atherosclerosis leading to cardiovascular events. 2 Of note, it is repeatedly revealed that psoriasis is an independent risk factor for the development of cardiovascular disease 3, 4 and that TNF inhibitors prevent cardiovascular events in patients with moderate to severe psoriasis. 5 Systemic autoimmune and/or inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, spondyloarthritides, and psoriasis, commonly manifest atherosclerosis as a result of chronic vascular inflammation. 2, [6] [7] [8] [9] During this process, proinflammatory cytokines, cell adhesion molecules, autoantibodies, oxidative stress, and/or dyslipidemia initiate and promote vascular damage, eventually resulting in the development of endothelial dysfunction. Endothelial dysfunction usually arises before the appearance of the first morphological signs of atherosclerosis; 10 therefore, the evaluation of endothelial In recent years, much attention has been focused on the benefit of TNF inhibitors for cardiovascular comorbidities in patients with psoriasis. 5, 20 Generally, TNF inhibitors exert a beneficial effect on endothelial function in patients with psoriasis, [21] [22] [23] but the association between drug effects on endothelial function and those on skin lesions has not been well studied.
Considering that an unfavorable long-term effect on skin lesions occurs in~20% of patients treated with infliximab, it is quite important to address this issue. Therefore, we investigated the association between infliximab effects on endothelial function and those on skin lesions in patients with psoriasis.
Materials and methods

Patients and treatment
We carried out a retrospective medical record review study based on our hospital admissions from 2013 to 2016. We found Table 1 . They had no history of cardiovascular disease.
Disease severity was assessed with the Psoriasis Area and Severity Index (PASI) score. We defined responders as patients who maintained PASI 75 response for more than 6 months 
Statistical analysis
Statistical analysis was performed using the Mann-Whitney Utest for comparison of two groups and the Wilcoxon signed-rank test for comparison before and after treatment. P value less than 0.05 was considered statistically significant.
Results
The effect of two infusions of infliximab on skin lesions and endothelial function in patients with psoriasis We examined the values of RHI in 15 patients with psoriasis before the first and third infusions of infliximab, namely, the second evaluation was carried out 4 weeks after the second infu- In the nine responders, PASI scores were significantly decreased at 6 weeks (P < 0.0001; Fig. 1a) , while the values of RHI were not altered (P = 0.25; Fig. 1c ). In the six nonresponders, in contrast to the responders, there was no significant difference in PASI scores at 6 weeks (P = 0.16; Fig. 1b) , while there was a trend toward the decrease in the values of RHI (P = 0.093; 
Discussion
A wealth of evidence suggests that TNF inhibitors decrease the risk of cardiovascular events in patients with moderate to severe psoriasis. Consistent with this notion, endothelial function, an indicator of atherosclerosis, has been reported to be favorably improved in patients with psoriasis treated with TNF inhibitors. [21] [22] [23] In this study, we focused our interest on the association between the efficacy of infliximab for endothelial function during the loading phase and the long-term effect of infliximab on skin lesions. Contrary to previous studies, we failed to detect the improvement of endothelial function before the third infusion of infliximab compared with the baseline, but we unexpectedly detected some patients with worsening of endothelial function. When looking at the long-term effect of infliximab on psoriatic skin lesions, we noticed that unfavorable outcome was observed in six out of 15 patients. Of note, these six nonresponders revealed a trend toward the decrease in endothelial function before the third infusion of infliximab. Furthermore, there was a significant difference in DRHI between the six nonresponders and the other nine responders. Moreover, the cutoff value, which was set at mean À 2 standard deviation of the RHI value of the responders, identified the nonresponder with 67% of sensitivity and 100% of specificity.
These results collectively indicate that the decrease in the RHI value before the third infusion of infliximab may serve as a pre- This scenario seems to be the case with our patients whose skin lesions poorly responded to infliximab even during the loading phase.
Our results seem to be contradictory to some previous stud- 
